Professors receive $3.7 million NIH grant to study effectiveness of higher-dosage buprenorphine among pregnant women with opioid use disorder
Grant and Award Announcement
Updates every hour. Last Updated: 29-Oct-2026 13:16 ET (29-Oct-2026 17:16 GMT/UTC)
Despite research supporting increased dosages as needed for buprenorphine, buprenorphine treatment during pregnancy is inconsistent and patients often receive inadequate dosages. Researchers at Boston University School of Public Health and Vanderbilt University School of Medicine are addressing this public health issue with a $3.7 million grant from the National Institute on Drug Abuse. Dr. Jake Morgan, research assistant professor of health law, policy & management at BUSPH, and Dr. Ashley Leech, assistant professor of health policy at Vanderbilt, have received the five-year award to evaluate the health and economic consequences of suboptimal buprenorphine dosing in pregnancy.
Erica Heinrich, an assistant professor of biomedical sciences in the UC Riverside School of Medicine, has received a $3.5 million grant from the National Institutes of Health’s National Heart, Lung, and Blood Institute to further study dyspnea — the clinical term for shortness of breath. The goals of the five-year project are to better understand the physiological signals associated with dyspnea, develop ways to identify when patients are suffering, and ultimately improve their care.
Getting sick can look very different for people with Down syndrome (DS); illnesses that are mild for most people may lead to serious complications, including pneumonia, hospitalization or intensive care.
Scientists have long known that excess hydrogen sulfide — a naturally occurring gas that becomes harmful when it accumulates in cells — has been a contributing factor for susceptibility to infections for people with DS. For years, researchers have believed that a chromosome 21 gene called CBS was largely responsible for this overproduction.
But now, researchers at the Texas A&M University College of Veterinary Medicine and Biomedical Sciences (VMBS) and the Texas A&M Health Institute of Biosciences and Technology (IBT) have identified evidence for a previously unknown pathway that may help explain those immune challenges.
The findings could provide a starting point for developing a new drug while also inspiring broader drug-design strategies that exploit similar structural features.